Onconova Therapeutics Inc (ONTX) stock has fallen 2.13% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With ONTX Stock Today?
Onconova Therapeutics Inc (ONTX) stock is trading at $6.90 as of 10:06 AM on Wednesday, Jun 2, an increase of $0.43, or 6.65% from the previous closing price of $6.47. The stock has traded between $6.45 and $6.95 so far today. Volume today is less active than usual. So far 225,456 shares have traded compared to average volume of 1,798,685 shares.
To see the top 5 stocks in the Biotechnology industry click here.
More About Onconova Therapeutics Inc
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Click Here to get the full Stock Score Report on Onconova Therapeutics Inc (ONTX) Stock.